Markets:

Overview

News

Currencies

International

Treasuries

Oric Pharmaceuticals, Inc. - Common Stock (NQ:ORIC)

13.50 +0.57 (+4.41%)

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Oric Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Top movers analysis one hour before the close of the markets on 2026-04-01: top gainers and losers in today's session. ↗

April 01, 2026

Via Chartmill

Keep an eye on the top gainers and losers in Wednesday's session. ↗

April 01, 2026

Via Chartmill

What's Behind The Drop In Oric Pharmaceuticals Stock Today? ↗

April 01, 2026

Shares of Oric Pharmaceuticals, Inc. (NASDAQ: ORIC) are tumbling Wednesday after the company announced an update from the Phase 1b trial of rinzimetostat in combination with darolutamide in patients...

Via Benzinga

These stocks are gapping in today's session ↗

April 01, 2026

Via Chartmill

Which stocks are moving before the opening bell on Wednesday? ↗

April 01, 2026

Via Chartmill

Top movers in Tuesday's after hours session ↗

March 31, 2026

Via Chartmill

Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. ↗

March 19, 2026

Relay Therapeutics develops precision oncology medicines using proprietary computational modeling and strategic industry partnerships.

Via The Motley Fool

Nextech Trims Kymera at a Recent High — think Foolishly before acting. ↗

March 19, 2026

Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing a diversified clinical pipeline.

Via The Motley Fool

Topics Regulatory Compliance

BETA Technologies, Starfighters Space And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

March 09, 2026

U.S. stock futures lower, with Dow futures down over 1%. BETA Technologies (NYSE: BETA) fell in pre-market trading after reporting fourth-quarter results. Other stocks declining in pre-market trading...

Via Benzinga

Topics Stocks

This Nasdaq Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗

November 20, 2025

Via Benzinga

This Bellring Brands Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday ↗

November 20, 2025

Via Benzinga

This Astera Labs Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

November 20, 2025

Via Benzinga

Nvidia To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Friday ↗

November 14, 2025

Via Benzinga

ORIC Pharmaceuticals Inc (NASDAQ:ORIC) Reports Q2 2025 Wider Loss but Extends Cash Runway with Strategic Restructuring ↗

August 12, 2025

ORIC Pharmaceuticals reports Q2 2025 results with a wider loss but extends cash runway to 2H 2028. Updates on ORIC-944 and enozertinib show progress in oncology trials.

Via Chartmill

Oric Pharma Stock Hits 3-Month High On Promising Results In Prostate Cancer Trial ↗

May 29, 2025

The company also announced a $125 million private placement to fund its upcoming Phase 3 trial for ORIC-944 in metastatic prostate cancer.

Via Stocktwits

Crude Oil Falls Over 1%; Best Buy Reports Downbeat Results ↗

May 29, 2025

Via Benzinga

Keep an eye on the top gainers and losers in Thursday's session. ↗

May 29, 2025

Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

ORIC Pharmaceuticals Touts Positive Efficacy, Safety Data From Early-Stage Prostate Cancer Candidate, Raises Capital ↗

May 29, 2025

ORIC's Phase 1b trial of ORIC-944 in mCRPC shows PSA responses and strong tolerability, with Phase 3 trials and financing plans underway.

Via Benzinga

The market is filled with gapping stocks in Thursday's session. ↗

May 29, 2025

Today's session on Thursday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Via Chartmill

Veeva Systems, e.l.f. Beauty, C3.ai, BRP And Other Big Stocks Moving Higher On Thursday ↗

May 29, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

May 29, 2025

Via Benzinga

Why Nvidia Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket ↗

May 29, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

May 28, 2025

Via Benzinga

Get insights into the top gainers and losers of Wednesday's after-hours session. ↗

May 28, 2025

As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

Via Chartmill

Tuesday's session: gap up and gap down stocks ↗

February 11, 2025

Let's have a look at the gap up and gap down stocks in today's session.

Via Chartmill

H&E Equipment Services, ACM Research, Robinhood And Other Big Stocks Moving Higher On Tuesday ↗

January 14, 2025

Via Benzinga

PriceSmart Posts Weak Earnings, Joins Roku And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

January 10, 2025

Via Benzinga

ORIC: Working with Two Pharma Giants, Analysts See +100% Upside

November 16, 2024

ORIC Pharmaceuticals is a stock analyst price targets currently signal double-bagger potential in. See what the excitement around this firm is all about.

Via MarketBeat

ORIC Stock Earnings: ORIC Pharmaceuticals Misses EPS for Q2 2024 ↗

August 12, 2024

ORIC stock results show that ORIC Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

ORIC Stock Earnings: ORIC Pharmaceuticals Beats EPS for Q1 2024 ↗

May 06, 2024

ORIC stock results show that ORIC Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.